These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13614321)

  • 1. [Lipoprotein disturbances in myeloma patients].
    WEISMANN-NETTER R; HIRSCH-MARIE H
    Presse Med (1893); 1958 Nov; 66(80):1787-8. PubMed ID: 13614321
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiple myeloma and lipid metabolism].
    Takatsuki K; Matsuzaki H
    Nihon Rinsho; 1983 Aug; 41(8):1878-81. PubMed ID: 6632300
    [No Abstract]   [Full Text] [Related]  

  • 3. Cholesterol levels in patients with multiple myeloma.
    Yavasoglu I; Tombuloglu M; Kadikoylu G; Donmez A; Cagirgan S; Bolaman Z
    Ann Hematol; 2008 Mar; 87(3):223-8. PubMed ID: 17874102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paper electrophoresis of glyco- and lipoproteins in blood in myeloma.
    TROPEANO L; POLOSA P
    Prog Med (Napoli); 1955 Feb; 11(3):65-8. PubMed ID: 14357464
    [No Abstract]   [Full Text] [Related]  

  • 5. Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients.
    Kimak E; Ksiazek A; Baranowicz-Gaszczyk I; Solski J
    Ren Fail; 2007; 29(6):705-12. PubMed ID: 17763166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma associated with sialyl salivary-type amylase.
    Shigemura M; Moriyama T; Shibuya H; Obara M; Endo T; Hashino S; Yokouchi H; Asaka M; Shimizu C; Chiba H; Nishimura M
    Clin Chim Acta; 2007 Feb; 376(1-2):121-5. PubMed ID: 16979610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperammonemia and encephalopathy in patients with multiple myeloma.
    Talamo G; Cavallo F; Zangari M; Barlogie B; Lee CK; Pineda-Roman M; Kiwan E; Krishna S; Tricot G
    Am J Hematol; 2007 May; 82(5):414-5. PubMed ID: 17133420
    [No Abstract]   [Full Text] [Related]  

  • 11. High Th1/Th2 ratio in patients with multiple myeloma.
    Ogawara H; Handa H; Yamazaki T; Toda T; Yoshida K; Nishimoto N; Al-ma'Quol WH; Kaneko Y; Matsushima T; Tsukamoto N; Nojima Y; Matsumoto M; Sawamura M; Murakami H
    Leuk Res; 2005 Feb; 29(2):135-40. PubMed ID: 15607360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudohyperphosphatemia in a patient with multiple myeloma.
    Marcu CB; Hotchkiss M
    Conn Med; 2004 Feb; 68(2):71-2. PubMed ID: 15007869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free plasma amino acids in patients with multiple myeloma.
    Loos U; Musch E; Schulte-Vennburg M; Ferber J
    J Chemother; 1989 Jul; 1(4 Suppl):1244-5. PubMed ID: 16312850
    [No Abstract]   [Full Text] [Related]  

  • 16. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
    Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
    Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.
    Palumbo A; Petrucci MT; Lauta VM; Musto P; Caravita T; Barbui AM; Nunzi M; Boccadoro M;
    Haematologica; 2005 Jun; 90(6):858-60. PubMed ID: 15951304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Properties and composition of serum albumin in multiple myeloma].
    CAPUTO A
    Z Krebsforsch; 1955; 60(3):372-8. PubMed ID: 14386976
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
    Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
    Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003.
    Zhou S
    Clin Cancer Res; 2003 Nov; 9(14):5429; author reply 5429. PubMed ID: 14614031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.